<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587961</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300001867</org_study_id>
    <nct_id>NCT03587961</nct_id>
  </id_info>
  <brief_title>Personalized Theratyping Trial</brief_title>
  <official_title>Personalized Theratyping Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the use of off-label CFTR modulators that may affect
      CFTR function in patients with CFTR mutations that are not currently approved for these
      drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to explore the use of off-label CFTR modulators that may affect
      CFTR function in patients with CFTR mutations that are not currently approved for these
      drugs. Symdeko (Tezacaftor/Ivacaftor), Orkambi (Ivacaftor and Lumacaftor), correctors of CFTR
      misfolding and Kalydeco (Ivacaftor), a potentiator of abnormal CFTR gating, will be explored
      as a treatment for patients with other CF mutations than those currently approved. Patients
      who have a mutation that responds to a CFTR corrector from in vitro study will be given
      Symdeko, or Orkambi, depending on the in vitro response pattern. Patients who have mutation
      response to a potentiator of CFTR function will be given Ivacaftor monotherapy. Patients with
      a mutation equivalent to wild type will be given Ivacaftor. If the patient is 6-12 years old,
      we will only study Orkambi or ivacaftor as symdeko is not yet FDA approved in this patient
      population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>spirometry</measure>
    <time_frame>32 weeks</time_frame>
    <description>change in lung function as measured via spirometry</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Symdeko</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Symdeko, depending on the in vitro response pattern</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivacaftor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have mutation response to a potentiator of CFTR function will be given Ivacaftor monotherapy.. Patients with a mutation equivalent to wild type will be given Ivacaftor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orkambi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Orkambi, depending on the in vitro response pattern</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symdeko</intervention_name>
    <description>explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.</description>
    <arm_group_label>Ivacaftor</arm_group_label>
    <arm_group_label>Orkambi</arm_group_label>
    <arm_group_label>Symdeko</arm_group_label>
    <other_name>Orkambi</other_name>
    <other_name>Ivacaftor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CF

          -  Age â‰¥6 y.o.

          -  CFTR mutation that may respond to approved correctors/potentiators in the opinion of
             the study investigators

          -  Informed Consent/Assent

          -  Stable CF pulmonary regimen

        Exclusion Criteria:

          -  Exacerbation requiring antibiotic or steroids for &gt;28 days before trial entry

          -  Ongoing participation in a CFTR modulator study

          -  Active smoking in the past 6 months

          -  History of solid organ transplant

          -  Any condition which precludes the use of CFTR modulators: e.g. advanced cirrhosis,
             End-stage Renal Disease (ESRD)

          -  Any condition that precludes the patient from participation in the opinion of the
             investigator

          -  Any meds that have significant drug-drug interactions or any other off label use of
             CFTR modulators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heather Hathorne, PhD</last_name>
    <phone>205-638-9568</phone>
    <email>hhathorne@peds.uab.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Hathorne, PhD</last_name>
      <phone>205-638-9568</phone>
      <email>hhathorne@peds.uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ginger Reeves, BS</last_name>
      <phone>205-638-5970</phone>
      <email>greeves@peds.uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>George Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>George Solomon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

